Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1188

Sort by

Sort Order Select

Journal Articles

Kinase inhibitors in CLL: drawing the roadmap

Nathan Fowler

Blood (2021) 137 (20): 2717–2719.

https://doi.org/10.1182/blood.2020010052

Published: 2021

Journal Articles

Characterization of Bypassing Kinases Inferred By Phosphoproteomics in a Midostaurin Resistant Myeloid Cell Line Model

Mahmoud Hallal, BSc, MSc, Sophie Braga-Lagache, MSc, Jovana Jankovic, Rémy Bruggmann, PhD, Ramanjaneyulu Allam, PhD MSc, BSc, Mario P. Tschan, PhD, Cédric Simillion, PhD, Manfred Heller, PhD, Nicolas Bonadies, MD

Blood (2019) 134 (Supplement_1): 2079.

https://doi.org/10.1182/blood-2019-122337

Published: 2019

Journal Articles

Pre-Clinical Efficacy of the Novel Kinase Inhibitor Nintedanib on PAX5 Fusion Genes in Pediatric Ph-like B-Cell Precursor Acute Lymphoblastic Leukemia

Grazia Fazio, Silvia Bresolin, Claudia Saitta, Daniela Silvestri, Elena Vendramini, Chiara Palmi, Silvia Rigamonti, Marta Galbiati, Manuel Quadri, Stefano Mecca, Angela Maria Savino, Michela Bardini, Andrea Grioni, Maria Grazia Valsecchi, PhD, Geertruy te Kronnie, Andrea Biondi, MD, Giovanni Cazzaniga, PhD

Blood (2019) 134 (Supplement_1): 745.

https://doi.org/10.1182/blood-2019-128509

Published: 2019

Journal Articles

Oncogene-Independent Adaptation of Pre-B Cell Receptor Signaling Confers Drug Resistance and Signaling Plasticity in Ph-like ALL

Christian Hurtz, PhD, Gerald Wertheim, MD, PhD, Joseph Patrick Loftus, BS, Daniel Blumenthal, PhD, Anne Lehman, Yong Li, Bryan Manning, Katherine D Cummins, BMBS, Janis K Burkhardt, PhD, Alexander E. Perl, MD, Martin Carroll, MD, Sarah K. Tasian, MD

Blood (2019) 134 (Supplement_1): 747.

https://doi.org/10.1182/blood-2019-123514

Published: 2019

Journal Articles

PP2A Activators Enhance Efficacy of FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells through AKT Inactivation-Dependent Pim-1 and c-Myc Proteasomal Degradation

Mario Scarpa, PhD, Prerna Singh, MS, Shivani Kapoor, MS, Jonelle K. Lee, MS, Sandrine Niyongere, MD, Goutham Narla, MD PhD, Danilo Perrotti, MD PhD, Maria R. Baer, MD

Blood (2019) 134 (Supplement_1): 1276.

https://doi.org/10.1182/blood-2019-129011

Published: 2019

Journal Articles

Activation of AKT/mTOR Pathway in Ph+ Acute Lymphoblastic Leukemia (ALL) Leads to Non-Mutational Resistance

Afsar Ali Mian, BSc, MPhil, PhD, Usva Zafar, BSc, Oliver Ottmann, Prof, MD, Martin Ruthardt, MD, El-Nasir M A Lalani, BSc MBChB FRCPath PhDFHEA

Blood (2019) 134 (Supplement_1): 2570.

https://doi.org/10.1182/blood-2019-130898

Published: 2019

Journal Articles

The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37 Targeted Radioimmunotherapy in Activated B Cell like Diffuse Large B Cell Lymphoma Cell Lines

Gro Elise Rødland, PhD, Katrine Melhus, Roman Generalov, Sania Gilani, Francesco Bertoni, MD, Jostein Dahle, PhD, Randi Syljuåsen, PhD, Sebastian Patzke, PhD

Blood (2019) 134 (Supplement_1): 2574.

https://doi.org/10.1182/blood-2019-123287

Published: 2019

Journal Articles

Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical, Clinical, and Correlative Studies

Jacqueline S Garcia, MD, Helen I. Gandler, Geoffrey Fell, MS, Ashlee J. Fiore, Donna S Neuberg, ScD, Adrienne Anderson, Kelsey O'Day, Marlise Luskin, MDMS, Martha Wadleigh, MD, Eric S. Winer, MD, Ilene Galinsky, Daniel J. DeAngelo, MD, David A. Frank, MD PhD, Richard M. Stone, MD

Blood (2019) 134 (Supplement_1): 2549.

https://doi.org/10.1182/blood-2019-126224

Published: 2019

Journal Articles

Clinical ALK5 Inhibitor, Vactosertib, Reverses TGFβ-1 Stimulated Smad-2 Driven Ineffective Hematopoiesis in MDS

Srinivas Aluri, Kimo Bachiashvili, MD, Anjali Budhathoki, MD, Tushar D Bhagat, PhD, Gaurav S Choudhary, PhD, Shanisha Gordon, Nandini Ramachandra, Kith Pradhan, PhD, Shahina Maqbool, Aditi Shastri, MD, Jung Im Huh, Sunjin Hwang, Kim Seong-Jin, PhD, Hui Zhang, Britta Will, PhD, Amittha Wickrema, PhD, Ulrich G. Steidl, MD PhD, Amit Verma, MBBS

Blood (2019) 134 (Supplement_1): 2990.

https://doi.org/10.1182/blood-2019-127561

Published: 2019

Journal Articles

Phase 1 Dose-Finding Study Investigating CA-4948, an IRAK4 Kinase Inhibitor, in Patients with R/R NHL: Report of Initial Efficacy and Updated Safety Information

Anas Younes, MD, Grzegorz Nowakowski, MD, Allison C. Rosenthal, DO, Lori A. Leslie, MD, Han W. Tun, MD, Matthew A. Lunning, DO, FACP, Iris Isufi, MD, Robert Martell, MD PhD, Krish Patel, MD

Blood (2019) 134 (Supplement_1): 5327.

https://doi.org/10.1182/blood-2019-131851

Published: 2019

Journal Articles

Cross-Talk between Cytokine and NF-ĸb Signaling in the CLL Microenvironment Can Affect Sensitivity for Venetoclax

Marco Haselager, MSc, Rachel Thijssen, Arnon P. Kater, Eric Eldering

Blood (2019) 134 (Supplement_1): 5449.

https://doi.org/10.1182/blood-2019-126788

Published: 2019

Journal Articles

Targeting MDM2 and XIAP By Idasanutlin in Diffuse Large B-Cell Lymphoma

Juan J. Gu, MD PhD, Samuel J. Thompson, Cory Mavis, MSc, Matthew J. Barth, MD, Pallawi Torka, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2019) 134 (Supplement_1): 5301.

https://doi.org/10.1182/blood-2019-129009

Published: 2019

Journal Articles

ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Mantle Cell Lymphoma (MCL) Cells

Håkan Mellstedt, MD PhD Prof., Amineh Ghaderi, MSc, Johanna Aschan, MSc, Fariba Mozaffari, MSc,PhD, Ali Moshfegh, MSc,PhD, Birgitta Sander, MD PhD Prof., Johan Schultz, MSc,PhD, Martin Norin, MSc,PhD, Thomas Olin, MSc,PhD, Elias Drakos, MD PhD Prof., George Z. Rassidakis, MD PhD Prof., Anders Österborg, MD PhD, Mohammad Hojjat-Farsangi, MSc,PhD

Blood (2019) 134 (Supplement_1): 5312.

https://doi.org/10.1182/blood-2019-129773

Published: 2019

Journal Articles

A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Entospletinib with and without Obinutuzumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Nadine Kutsch, MD, Christian Pallasch, Eugen Tausch, Volkmar Boehme, Matthias Ritgen, Ruediger Liersch, Alexander Wacker, Georg Jacobs, Ralf Ulrich Trappe, Peter Dreger, Stephan Stilgenbauer, Danjie Zhang, Juliane M. Jürgensmeier, Pankaj Bhargava, Michael Hallek, Barbara F. Eichhorst, MD

Blood (2019) 134 (Supplement_1): 4297.

https://doi.org/10.1182/blood-2019-130912

Published: 2019

Journal Articles

Identification of Genotype-Specific Therapeutic Vulnerabilities By Comparative Dynamic BH3 Profiling Analysis of Human and Murine CLL

Shanye Yin, PhD, Salma Parvin, PhD, Elisa Ten Hacken, PhD, Rebecca Valentin, MD, Heather Joyal, Laura Z. Rassenti, PhD, Emanuela M. Ghia, PhD, Thomas J. Kipps, MD PhD, Donna S Neuberg, ScD, Lili Wang, MD PhD, Matthew S. Davids, MD, Ruben D. Carrasco, MD PhD, Anthony G. Letai, MD PhD, Catherine J. Wu, MD

Blood (2019) 134 (Supplement_1): 4281.

https://doi.org/10.1182/blood-2019-127293

Published: 2019

Journal Articles

Bromodomain and Extra Terminal Domain (BET) Inhibitors Sensitize Chronic Myelomonocytic Leukemia (CMML) to PIM Inhibition Via Downregulation of Mir-33a

Blood (2019) 134 (Supplement_1): 4220.

https://doi.org/10.1182/blood-2019-128165

Published: 2019

Journal Articles

Prospective, Comprehensive Cardiac Assessment in Patients Receiving BTK Inhibitor Therapy

Chloe Pek Sang Tang, MBBS, FRACP, Andre La Gerche, Julie McMullen, BSc(Hons) PhDFCSANZ FAHA, Erin Howden, Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, Isaac Goncalves, MBBS PhDFRACP, Jenny Ooi, Constantine S. Tam, MBBS (Hons), MD

Blood (2019) 134 (Supplement_1): 4301.

https://doi.org/10.1182/blood-2019-129808

Published: 2019

Journal Articles

The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Novel Comorbidity Score Derived from a Large Multicenter Retrospective Cohort Study of Patients Treated with Ibrutinib and/or Chemo-Immunotherapy (CIT)

Max J. Gordon, MD, Andy Kaempf, Andrea Sitlinger, MD, Tareq Salous, Hamood Alqahtani, MBBS, Michael C. Churnetski, Paul Wisniewski, Xavier Issac Rivera, BS, Krish Patel, MD, Daniel O. Persky, MD, Jonathon B. Cohen, MDMS, Michael Y. Choi, MD, Brian T. Hill, MD, Mazyar Shadman, MD, Deborah M. Stephens, DO, Danielle M. Brander, MD, Byung Park, PhD, Alexey Danilov, MD PhD

Blood (2019) 134 (Supplement_1): 4286.

https://doi.org/10.1182/blood-2019-124631

Published: 2019

Journal Articles

CSF3R Mutations Are Exceedingly Rare Genetic Events Associated with Inferior Survival and Sensitivity to Ruxolitinib across Myeloid Malignancies

Anthony M. Hunter, MD, Nelson Ryan, PharmD, Mohammad Hussaini, MD, Ratilal Akabari, Alan F. List, MD, Jeffrey Lancet, MD, David A Sallman, MD, Rami S. Komrokji, MD, Javier Pinilla Ibarz, MD PhD, Andrew T Kuykendall, MD, Ling Zhang, MD, Eric Padron, MD

Blood (2019) 134 (Supplement_1): 4167.

https://doi.org/10.1182/blood-2019-130196

Published: 2019

Journal Articles

Overexpression of Mir-21-5p Induces Apoptosis and Cell Cycle Arrest By Down-Regulating SKP2 and Overcomes Bortezomib Resistance in Multiple Myeloma

Jonahunnatha Nesson George William, PhD, Jian Wu, MD, Ziyan Chen, Omar Faruq, PhD, Hong Chang, MD

Blood (2019) 134 (Supplement_1): 1823.

https://doi.org/10.1182/blood-2019-128917

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Kinase inhibitors in CLL: drawing the roadmap

Characterization of Bypassing Kinases Inferred By Phosphoproteomics in a Midostaurin Resistant Myeloid Cell Line Model

Pre-Clinical Efficacy of the Novel Kinase Inhibitor Nintedanib on PAX5 Fusion Genes in Pediatric Ph-like B-Cell Precursor Acute Lymphoblastic Leukemia

Oncogene-Independent Adaptation of Pre-B Cell Receptor Signaling Confers Drug Resistance and Signaling Plasticity in Ph-like ALL

PP2A Activators Enhance Efficacy of FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells through AKT Inactivation-Dependent Pim-1 and c-Myc Proteasomal Degradation

Activation of AKT/mTOR Pathway in Ph+ Acute Lymphoblastic Leukemia (ALL) Leads to Non-Mutational Resistance

The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37 Targeted Radioimmunotherapy in Activated B Cell like Diffuse Large B Cell Lymphoma Cell Lines

Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical, Clinical, and Correlative Studies

Clinical ALK5 Inhibitor, Vactosertib, Reverses TGFβ-1 Stimulated Smad-2 Driven Ineffective Hematopoiesis in MDS

Phase 1 Dose-Finding Study Investigating CA-4948, an IRAK4 Kinase Inhibitor, in Patients with R/R NHL: Report of Initial Efficacy and Updated Safety Information

Cross-Talk between Cytokine and NF-ĸb Signaling in the CLL Microenvironment Can Affect Sensitivity for Venetoclax

Targeting MDM2 and XIAP By Idasanutlin in Diffuse Large B-Cell Lymphoma

ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Mantle Cell Lymphoma (MCL) Cells

A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Entospletinib with and without Obinutuzumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Identification of Genotype-Specific Therapeutic Vulnerabilities By Comparative Dynamic BH3 Profiling Analysis of Human and Murine CLL

Bromodomain and Extra Terminal Domain (BET) Inhibitors Sensitize Chronic Myelomonocytic Leukemia (CMML) to PIM Inhibition Via Downregulation of Mir-33a

Prospective, Comprehensive Cardiac Assessment in Patients Receiving BTK Inhibitor Therapy

The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Novel Comorbidity Score Derived from a Large Multicenter Retrospective Cohort Study of Patients Treated with Ibrutinib and/or Chemo-Immunotherapy (CIT)

CSF3R Mutations Are Exceedingly Rare Genetic Events Associated with Inferior Survival and Sensitivity to Ruxolitinib across Myeloid Malignancies

Overexpression of Mir-21-5p Induces Apoptosis and Cell Cycle Arrest By Down-Regulating SKP2 and Overcomes Bortezomib Resistance in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only